The FDA granted accelerated approval on September 4, 2026 to Etcamah (camizestrant), from AstraZeneca, for a common form of advanced breast cancer. The notable part is not the drug but its trigger: treatment begins when a blood test detects a resistance mutation, before imaging shows the disease progressing.

The approved indication

Etcamah is approved in combination with a CDK4/6 inhibitor — abemaciclib, palbociclib or ribociclib — for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer, once an ESR1 mutation is detected during aromatase inhibitor plus CDK4/6 inhibitor therapy.

The companion diagnostic is the Guardant360 CDx assay, which identifies ESR1 mutations from a blood sample.

What an ESR1 mutation actually signifies

Hormone-receptor-positive breast cancer depends on oestrogen signalling to grow, which is why standard first-line therapy combines an aromatase inhibitor — cutting oestrogen production — with a CDK4/6 inhibitor that blocks cell-cycle progression. The combination works well, and then, in most patients, stops working.

A common escape route is mutation in ESR1, the gene encoding the oestrogen receptor itself. Certain mutations leave the receptor constitutively active — switched on without needing oestrogen at all. At that point, starving the tumour of oestrogen becomes futile, because the receptor no longer waits for it.

Camizestrant belongs to a class designed for exactly this situation: it degrades the oestrogen receptor rather than merely blocking oestrogen supply, removing the mutated protein instead of trying to deprive it.

Why the blood test is the real news

This is, per the FDA, the first cancer therapy approved on the basis of detecting a resistance mutation in circulating tumour DNA — a liquid biopsy — before the cancer visibly progresses on scans.

Conventional oncology practice is reactive. A patient continues on therapy while periodic imaging is performed, and when scans show growth, treatment is switched. The problem is that radiographic progression is a late signal: by the time a tumour is measurably larger, the resistant population has been expanding for some time.

Tumours shed DNA into the bloodstream continuously, and sequencing that DNA can detect an emerging ESR1 mutation while the disease still appears controlled. The new approach acts on that molecular warning — switching therapy at the first genomic sign of resistance rather than waiting for its anatomical consequences.

The evidence

Median progression-free survival was 16 months with Etcamah plus a CDK4/6 inhibitor, versus 9.2 months for continuing an aromatase inhibitor plus CDK4/6 inhibitor.

“Today’s approval delivers a win to these patients by granting them a targeted therapy,” said acting Commissioner Kyle Diamantas.

What accelerated approval means here

The approval is accelerated, granted on a surrogate endpoint, with confirmatory studies required to verify clinical benefit.

The specific uncertainty is worth naming. Progression-free survival measures how long before the cancer worsens; it does not establish that patients live longer. Switching therapy earlier can extend the interval before radiographic progression partly by definition — the new drug is introduced while disease is still controlled. Whether acting on the molecular signal translates into an overall survival benefit, rather than reordering when therapies are used, is the question confirmatory data must answer.

Safety

The label carries a boxed warning for irregular heart rhythm when combined with certain medications, along with warnings for abnormally slow heart rate and fetal harm. A boxed warning is the FDA’s most serious labelling designation, and it means drug-interaction review is a practical requirement rather than a formality — relevant in a population often taking multiple medicines.

Camizestrant is not the first drug for this problem

Context is useful here, because the molecule is more evolutionary than the coverage suggests. Drugs that degrade the oestrogen receptor rather than merely blocking it have existed for years: fulvestrant established the mechanism, though it requires intramuscular injection, which limits how conveniently it can be used. Elacestrant, approved in 2023, was the first oral drug in the class specifically indicated for ESR1-mutated advanced breast cancer, and it is used after progression on endocrine therapy.

Against that background, what distinguishes this approval is when the drug is started rather than what it does. Elacestrant addresses ESR1-mutated disease that has already progressed. Etcamah is indicated when the mutation appears in blood while the disease still looks controlled. Same class of problem, moved earlier in the sequence — which is precisely why the trial had to be designed around molecular monitoring rather than imaging.

Why this could become a template

The logic generalises beyond breast cancer. Many targeted therapies fail through identifiable resistance mutations, and ctDNA can in principle detect any of them. If monitoring for a known escape mutation and switching pre-emptively proves durable here, the same design becomes attractive across other cancers with well-characterised resistance pathways.

Two things would need to hold. Confirmatory studies must show the strategy delivers benefit patients feel, not just a longer interval on a scan. And the monitoring itself must be affordable and available — a treatment paradigm requiring serial liquid biopsies assumes routine access to sequencing that many health systems do not currently provide. Regulatory news, not medical advice.